24-Apr-2024
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Business Wire (Wed, 24-Apr 8:30 AM ET)
Edgewise gets EU orphan drug status for muscular dystrophy drug
Seeking Alpha News (Tue, 23-Apr 10:29 AM ET)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 29-Mar 4:00 PM ET)
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Business Wire (Mon, 4-Mar 8:30 AM ET)
Business Wire (Thu, 29-Feb 9:00 AM ET)
Business Wire (Wed, 28-Feb 4:05 PM ET)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Business Wire (Wed, 21-Feb 8:30 AM ET)
Business Wire (Fri, 16-Feb 7:00 AM ET)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of April 24, 2024, SRPT stock price climbed to $124.25 with 1,246,359 million shares trading.
SRPT has a beta of 0.09, meaning it tends to be less sensitive to market movements. SRPT has a correlation of 0.00 to the broad based SPY ETF.
SRPT has a market cap of $11.57 billion. This is considered a Large Cap stock.
Last quarter Sarepta Therapeutics reported $397 million in Revenue and $.82 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.81.
In the last 3 years, SRPT stock traded as high as $159.89 and as low as $55.25.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): VTI, VB, VXF, VBK, IBB.
SRPT has underperformed the market in the last year with a return of -1.9%, while the SPY ETF gained +24.1%. In the last 3 month period, SRPT fell short of the market, returning +3.4%, while SPY returned +4.5%. However, in the most recent 2 weeks SRPT has outperformed the stock market by returning -1.6%, while SPY returned -1.7%.
SRPT support price is $114.71 and resistance is $119.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT stock will trade within this expected range on the day.